Voyager Therapeutics, Inc.VYGRNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank72
3Y CAGR-1.5%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-1.5%/yr
vs +98.8%/yr prior
Acceleration
-100.3pp
Decelerating
Percentile
P72
Within normal range
vs 3Y Ago
1x
Modest growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 15.11% |
| Q3 2025 | -22.89% |
| Q2 2025 | 8.87% |
| Q1 2025 | 7.18% |
| Q4 2024 | 10.11% |
| Q3 2024 | -19.54% |
| Q2 2024 | 17.94% |
| Q1 2024 | -15.96% |
| Q4 2023 | 24.03% |
| Q3 2023 | -0.43% |
| Q2 2023 | -8.13% |
| Q1 2023 | 6.69% |
| Q4 2022 | 15.81% |
| Q3 2022 | -3.24% |
| Q2 2022 | -1.40% |
| Q1 2022 | -8.29% |
| Q4 2021 | -4.17% |
| Q3 2021 | -16.51% |
| Q2 2021 | 7.11% |
| Q1 2021 | 17.82% |
| Q4 2020 | -0.08% |
| Q3 2020 | 0.46% |
| Q2 2020 | -19.27% |
| Q1 2020 | 3.18% |
| Q4 2019 | 16.87% |
| Q3 2019 | 1.69% |
| Q2 2019 | -13.84% |
| Q1 2019 | 17.01% |
| Q4 2018 | 24.91% |
| Q3 2018 | -43.81% |
| Q2 2018 | 63.77% |
| Q1 2018 | 33.84% |
| Q4 2017 | 8.58% |
| Q3 2017 | 9.43% |
| Q2 2017 | -8.10% |
| Q1 2017 | 41.17% |
| Q4 2016 | 3.29% |
| Q3 2016 | 18.08% |
| Q2 2016 | -19.94% |
| Q1 2016 | 12.92% |